Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 9;40(26):3506-3510.
doi: 10.1016/j.vaccine.2022.02.040. Epub 2022 Feb 17.

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Erin Sparrow  1 , Ifedayo Adetifa  2 , Nathorn Chaiyakunapruk  3 , Thomas Cherian  4 , Deshayne B Fell  5 , Barney S Graham  6 , Bruce Innis  7 , David C Kaslow  7 , Ruth A Karron  8 , Harish Nair  9 , Kathleen M Neuzil  10 , Samir Saha  11 , Peter G Smith  12 , Padmini Srikantiah  13 , Fred Were  14 , Heather J Zar  15 , Daniel Feikin  16
Affiliations

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Erin Sparrow et al. Vaccine. .

Abstract

World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

Keywords: Monoclonal antibody; Passive immunization; Respiratory syncytial virus.

PubMed Disclaimer

References

    1. Shi T., McAllister D.A., O'Brien K.L., Simoes E.A.F., Madhi S.A., Gessner B.D., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. - PMC - PubMed
    1. Driscoll A.J., Arshad S.H., Bont L., Brunwasser S.M., Cherian T., Englund J.A., et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine. 2020;38(11):2435–2448. - PMC - PubMed
    1. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016– conclusions and recommendations. Weekly epidemiological record, 27 May 2016; available here: (accessed 16 August 2021).
    1. PATH RSV Vaccine and mAb Snapshot April 2021 (www.path.org/resources/rsv-vaccine-and-mab-snapshot/, accessed on 18 August 2021).
    1. Astra Zeneca Press Release 26 April 2021, Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants. (available here: https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-..., accessed on 19 August 2021.

Substances